Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 9, 2002, Pages 47-49

  Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036310169     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34275     Document Type: Conference Paper

References (7)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
2. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
3. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
4. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
5. Single-agent activity of gemcitabine in advanced non-small cell lung cancer
6. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
7. A phase I-II study of gemcitabine and paclitaxel in advanced non-small cell lung cancer patients